The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

This trial is testing whether iguratimod (IGU), an anti-inflammatory drug, is effective and safe in people with primary Sjögren's syndrome — an autoimmune disease that causes severe dry eyes and dry mouth by attacking the glands that produce moisture. **You may be eligible if...** - You have been diagnosed with primary Sjögren's syndrome - You have symptoms of dry eyes and dry mouth - You test positive for the anti-SSA/Ro-60 antibody - You have not taken hormones, immunosuppressants, or biological drugs in the past 4 weeks **You may NOT be eligible if...** - You are pregnant, breastfeeding, or planning to become pregnant - You have another autoimmune condition or cancer - You have serious problems with your heart, liver, kidney, lungs, or blood counts - You are allergic to iguratimod or hydroxychloroquine Talk to your doctor to see if this trial is right for you.